Lapatinib Completed Phase 2 Trials for Newly Diagnosed / ErbB2 Overexpressing / ErbB1 Expressing / Neoplasms, Breast / Inflammatory / Cancer, Breast Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00206427Neoadjuvant GW572016 to Treat Breast Cancer
NCT00356811Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
NCT00721630Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
NCT01485926A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.
NCT00089999Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
NCT00429299Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
NCT00347919Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
NCT00524303Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
NCT00105950Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
NCT00558103Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
NCT00482391Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
NCT00422903Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
NCT00299286Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer
NCT00062686GW572016 For Treatment Of Refractory Metastatic Breast Cancer
NCT01973660PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
NCT00320411GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
NCT00709761Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
NCT01275859Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer
NCT00769470Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00111787Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
NCT008262676 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
NCT00548184Lapatinib and Trastuzumab With or Without Endocrine Therapy
NCT01068704Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
NCT00263588Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer